Introduction to Refractory Colorectal

What is/are Refractory Colorectal?

Refractory Colorectal - Background Patients with refractory colorectal (CRC) cancer have few treatment options. ^[1] 131Background: For patients with metastatic RAS/RAF wild-type refractory colorectal cancer anti-EGFR therapy can be reused in subsequent lines of therapy. ^[2] Conclusion This phase 1 study showed that the combination of oral CKD-516 and irinotecan is safe and tolerable in metastatic, treatment-refractory colorectal patients and showed favorable efficacy outcomes. ^[3] Conclusions: This case describes the safe and effective use of a biodegradable PDS stent for refractory colorectal anastomotic stricture. ^[4] Subsequent efforts to optimise 5-FU-based treatments have focused on 5-FU analogues, initially capecitabine and the combination drug tegafur/gimeracil/oteracil (S-1) and then TAS-102, which has recently been evaluated in phase 3 clinical trials for refractory colorectal cancer. ^[5] The further assessment of FOLFOXIRI regimen for refractory colorectal cancer in the prospective trials is needed. ^[6] Conclusions The tumoroid yield after cultivation of biopsies from chemo-refractory colorectal cancer patients correlates with the level of carcinoma cells determined by microscopy and probably with the stiffness of the metastasis. ^[7] Apatinib monotherapy showed promising efficiency for patients with refractory colorectal cancer, especially in patients with PS 0–1 or no liver metastasis. ^[8] MethodRetrospective, multicenter, and observational study including patients with advanced refractory colorectal cancer who started TAS-102 between March 2016 and August 2018. ^[9] Together, our study illuminates the downregulation of multiple ABC transporters as a mechanism by which OPCs overcome chemoresistance in cancer cells and may serve as adjunctive treatments in patients with refractory colorectal cancer. ^[10] Because trifluridine (FTD)/tipiracil therapy is used for refractory colorectal cancer, we sought to determine whether FTD is effective against CSC-like cells. ^[11] AIMS Patients with chemotherapy-refractory colorectal cancer liver metastases have limited therapeutic options. ^[12] This study investigates whether the ctDNA monitoring of one driver gene mutation, provides enough information as compared to multiple mutations to assess response to regorafenib in advanced chemorefractory colorectal cancer (aCRC) at an early timepoint. ^[13] We conducted a multihistology phase I/II trial of TRC102 in combination with TMZ in patients (pts) with refractory solid tumors (NCT01851369); here we report the clinical activity of this combination in the phase II refractory colorectal carcinoma (CRC) cohort. ^[14] : TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. ^[15] The primary objective of the trial was to identify the maximum tolerated dose of TP-0903 prior to expanding into refractory colorectal, platinum refractory/resistant ovarian cancer and TP-0903 in combination with immunotherapy or EGFR tyrosine kinase inhibitor in immunotherapy-resistant tumors or non-small cell lung cancers. ^[16] TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. ^[17]

Metastatic Refractory Colorectal

: TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. ^[1] TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. ^[2]

refractory colorectal cancer

131Background: For patients with metastatic RAS/RAF wild-type refractory colorectal cancer anti-EGFR therapy can be reused in subsequent lines of therapy. ^[1] Subsequent efforts to optimise 5-FU-based treatments have focused on 5-FU analogues, initially capecitabine and the combination drug tegafur/gimeracil/oteracil (S-1) and then TAS-102, which has recently been evaluated in phase 3 clinical trials for refractory colorectal cancer. ^[2] The further assessment of FOLFOXIRI regimen for refractory colorectal cancer in the prospective trials is needed. ^[3] Conclusions The tumoroid yield after cultivation of biopsies from chemo-refractory colorectal cancer patients correlates with the level of carcinoma cells determined by microscopy and probably with the stiffness of the metastasis. ^[4] Apatinib monotherapy showed promising efficiency for patients with refractory colorectal cancer, especially in patients with PS 0–1 or no liver metastasis. ^[5] MethodRetrospective, multicenter, and observational study including patients with advanced refractory colorectal cancer who started TAS-102 between March 2016 and August 2018. ^[6] Together, our study illuminates the downregulation of multiple ABC transporters as a mechanism by which OPCs overcome chemoresistance in cancer cells and may serve as adjunctive treatments in patients with refractory colorectal cancer. ^[7] Because trifluridine (FTD)/tipiracil therapy is used for refractory colorectal cancer, we sought to determine whether FTD is effective against CSC-like cells. ^[8] AIMS Patients with chemotherapy-refractory colorectal cancer liver metastases have limited therapeutic options. ^[9] This study investigates whether the ctDNA monitoring of one driver gene mutation, provides enough information as compared to multiple mutations to assess response to regorafenib in advanced chemorefractory colorectal cancer (aCRC) at an early timepoint. ^[10] : TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. ^[11] TAS-102 represents an important therapeutic resource for patients with metastatic refractory colorectal cancer. ^[12]